Citations (25)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Ho Yeon Chung, Jawon Koo, Su Kyoung Kwon, Moo-IL Kang, Seong-Hwan Moon, Jin-Young Park, Chan Soo Shin, Byung-Koo Yoon, Hyun-Koo Yoon, Jae-Suk Chang, Yoon-Sok Chung & Hyoung-Moo Park. (2013) Early changes in 25-hydroxyvitamin D levels and bone markers after monthly risedronate with cholecalciferol in Korean patients with osteoporosis. Clinical Interventions in Aging 8, pages 597-603.
Read now
Read now
Luca Dalle Carbonare, Mirko Zanatta, Adriano Gasparetto & Maria Teresa Valenti. (2010) Safety and tolerability of zoledronic acid and other bisphosphonates in osteoporosis management. Drug, Healthcare and Patient Safety 2, pages 121-137.
Read now
Read now
Julian MR Mathoo, Lisa Becker, Dinesh Kumbhare & Jonathan D Adachi. (2007) Therapeutic advances in the treatment of osteoporosis. Expert Opinion on Therapeutic Patents 17:3, pages 277-285.
Read now
Read now
Articles from other publishers (22)
José Reginaldo Alves de Queiroz Júnior, Jarson Pedro da Costa Pereira, Leonardo Lucas Pires & Carina Scanoni Maia. (2022) Alendronato de sódio e vitamina D na osteoporose pós-menopausa. Scientia Medica 32:1, pages e42267.
Crossref
Crossref
Mehrnaz Moradinejad, Marzie Yazdi, Seyed Ali Mard, Seyed Mohammad Razavi, Milad Shamohammadi, Fatemeh Shahsanaei & Vahid Rakhshan. (2022) Efficacy of the systemic co-administration of vitamin D3 in reversing the inhibitory effects of sodium alendronate on orthodontic tooth movement: A preliminary experimental animal study. American Journal of Orthodontics and Dentofacial Orthopedics 162:1, pages e17-e27.
Crossref
Crossref
Racquel Jandoc, Muhammad Mamdani, Linda E. Lévesque & Suzanne M. Cadarette. (2016) Urban–rural differences in the uptake of new oral bisphosphonate formulations. Archives of Osteoporosis 11:1.
Crossref
Crossref
R. Cesareo, E. Di Stasio, F. Vescini, G. Campagna, R. Cianni, V. Pasqualini, F. Romitelli, F. Grimaldi, S. Manfrini & A. Palermo. (2014) Effects of alendronate and vitamin D in patients with normocalcemic primary hyperparathyroidism. Osteoporosis International 26:4, pages 1295-1302.
Crossref
Crossref
In-Jin ChoHo-Yeon ChungSung-Woon KimJae-Won LeeTae-Won LeeHye-Soon KimSin-Gon KimHan Seok ChoiSung-Hee ChoiChan Soo ShinKi-Won OhYong-Ki MinJung-Min KohYumie RheeDong-Won ByunYoon-Sok ChungJeong Hyun ParkDong Jin ChungMinho ShongEun-Gyoung HongChang Beom LeeKi Hyun BaekMoo-Il Kang. (2015) Efficacy of a Once-Monthly Pill Containing Ibandronate and Cholecalciferol on the Levels of 25-Hydroxyvitamin D and Bone Markers in Postmenopausal Women with Osteoporosis. Endocrinology and Metabolism 30:3, pages 272.
Crossref
Crossref
Jeri W. Nieves & Felicia Cosman. 2015. Nutrition and Bone Health. Nutrition and Bone Health
681
686
.
Kwang Joon KimYong-Ki MinJung-Min KohYoon-Sok ChungKyoung Min KimDong-Won ByunIn Joo KimMikyung KimSung-Soo KimKyung Wan MinKi Ok HanHyoung Moo ParkChan Soo ShinSung Hee ChoiJong Suk ParkDong Jin ChungJi Oh MokHong Sun BaekSeong-Hwan MoonYong Soo KimSung-Kil Lim. (2014)
Efficacy and Safety of Weekly Alendronate Plus Vitamin D
3
5600 IU versus Weekly Alendronate Alone in Korean Osteoporotic Women: 16-Week Randomized Trial
. Yonsei Medical Journal 55:3, pages 715.
Crossref
Crossref
Ji Hyun LeeByung Chul JeeChang Suk SuhSeok Hyun KimYoung Min ChoiJung Gu KimShin Yong Moon. (2013) Comparison of the efficacy of three once-weekly bisphosphonates on bone mineral density gains in Korean women. Obstetrics & Gynecology Science 56:3, pages 176.
Crossref
Crossref
Tae Nyun KimKyung Mook Choi. (2013) Sarcopenia: Definition, Epidemiology, and Pathophysiology. Journal of Bone Metabolism 20:1, pages 1.
Crossref
Crossref
Huifeng Yun, Jeffrey R Curtis, Kenneth Saag, Meredith Kilgore, Paul Muntner, Wilson Smith, Robert Matthews, Nicole Wright, Michael A. Morrisey & Elizabeth Delzell. (2013) Generic alendronate use among medicare beneficiaries: are part d data complete?. Pharmacoepidemiology and Drug Safety 22:1, pages 55-63.
Crossref
Crossref
Marco Brotto & Eduardo L. Abreu. (2012) Sarcopenia: Pharmacology of Today and Tomorrow. Journal of Pharmacology and Experimental Therapeutics 343:3, pages 540-546.
Crossref
Crossref
Andrew E. Denker, Nicole Lazarus, Arturo Porras, Rohini Ramakrishnan, Marvin Constanzer, Boyd R. Scott, Cynthia Chavez-Eng, Eric Woolf, Lata Maganti, Patrick Larson, Keith Gottesdiener & John A. Wagner. (2011)
Bioavailability of Alendronate and Vitamin D
3
in an Alendronate/Vitamin D
3
Combination Tablet
. The Journal of Clinical Pharmacology 51:10, pages 1439-1448.
Crossref
Crossref
Mohamed B. Elamin, Nisrin O. Abu Elnour, Khalid B. Elamin, Mitra M. Fatourechi, Aziz A. Alkatib, Jaime P. Almandoz, Hau Liu, Melanie A. Lane, Rebecca J. Mullan, Ahmad Hazem, Patricia J. Erwin, Donald D. Hensrud, Mohammad Hassan Murad & Victor M. Montori. (2011) Vitamin D and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis. The Journal of Clinical Endocrinology & Metabolism 96:7, pages 1931-1942.
Crossref
Crossref
Ho-Yeon Chung, Sang Ouk Chin, Moo-IL Kang, Jung-Min Koh, Sung-Hwan Moon, Byung-Koo Yoon, Hyun-Koo Yoon, Yoon-Sok Chung & Hyoung-Moo Park. (2011) Efficacy of risedronate with cholecalciferol on 25-hydroxyvitamin D level and bone turnover in Korean patients with osteoporosis. Clinical Endocrinology 74:6, pages 699-704.
Crossref
Crossref
Andrew C Karaplis, Fridon Chouha, Michel Djandji, John S Sampalis & David A Hanley. (2011)
Vitamin D Status and Response to Daily 400 IU Vitamin D
3
and Weekly Alendronate 70 mg in Men and Women with Osteoporosis
. Annals of Pharmacotherapy 45:5, pages 561-568.
Crossref
Crossref
Jee-Hoon KooHyun-Kyung KimIn-Sung KimEun-Kyung KimYoon-Sok Chung. (2010) The Effects of Combined Treatment of Alendronate Plus Active or Plain Vitamin D on the Vitamin D Metabolism and Bone Turnover Markers in Patients with Osteoporosis. Endocrinology and Metabolism 25:4, pages 305.
Crossref
Crossref
William F Lems & Piet Geusens. (2009) Are bisphosphonates effective and safe in patients with low serum vitamin D levels?. International Journal of Clinical Rheumatology 4:2, pages 119-121.
Crossref
Crossref
Neil Binkley, Johann D. Ringe, John I. Reed, Östen Ljunggren, Michael F. Holick, Helmut W. Minne, Minzhi Liu, Amy Lamotta, Joseph A. West & Arthur C. Santora. (2009) Alendronate/vitamin D3 70 mg/2800 IU with and without additional 2800 IU vitamin D3 for osteoporosis: Results from the 24-week extension of a 15-week randomized, controlled trial. Bone 44:4, pages 639-647.
Crossref
Crossref
J.M. Quesada Gómez. (2008) . Revista Española de Enfermedades Metabólicas Óseas 17:4, pages 85-86.
Crossref
Crossref
Claude Laurent Benhamou. (2008) Les carences et insuffisances en vitamine D : une situation largement répandue, des mesures préventives à mettre en place. La Presse Médicale 37:2, pages 187-190.
Crossref
Crossref
Shinjiro Takata, Aziz Abbaspour, Hiroshi Yonezu & Natsuo Yasui. (2007) Differences of therapeutic effects on regional bone mineral density and markers of bone mineral metabolism between alendronate and alfacalcidol in Japanese osteoporotic women. The Journal of Medical Investigation 54:1,2, pages 35-40.
Crossref
Crossref
Sol Epstein. (2006) The Problem of Low Levels of Vitamin D and Osteoporosis. Drugs & Aging 23:8, pages 617-625.
Crossref
Crossref